Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation”

83 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 83 results

Early research (Phase 1)Ended earlyNCT06130254
What this trial is testing

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Who this might be right for
Advanced Solid TumorNon-small Cell Lung Cancers
M.D. Anderson Cancer Center 1
Testing effectiveness (Phase 2)Looking for participantsNCT06128551
What this trial is testing

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Colorectal CancerPancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc. 534
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772
What this trial is testing

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 247
Testing effectiveness (Phase 2)Looking for participantsNCT06582771
What this trial is testing

Sotorasib in People With Non-Small Cell Lung Cancer

Who this might be right for
Non Small Lung Cancer
Memorial Sloan Kettering Cancer Center 39
Testing effectiveness (Phase 2)Active Not RecruitingNCT04625647
What this trial is testing

Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Who this might be right for
Lung AdenocarcinomaLung Non-Small Cell CarcinomaRecurrent Lung Non-Squamous Non-Small Cell Carcinoma+3 more
SWOG Cancer Research Network 116
Early research (Phase 1)Study completedNCT04967079
What this trial is testing

Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients

Who this might be right for
Non Small Cell Lung Cancer
Shanghai Chest Hospital 33
Testing effectiveness (Phase 2)Looking for participantsNCT06244771
What this trial is testing

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

Who this might be right for
Advanced Solid Tumors With KRAS G12C MutationsSolid Tumor, AdultUnresectable Solid Tumor+5 more
Frontier Medicines Corporation 403
Large-scale testing (Phase 3)Looking for participantsNCT06875310
What this trial is testing

Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Mirati Therapeutics Inc. 630
Testing effectiveness (Phase 2)Looking for participantsNCT07198841
What this trial is testing

IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

Who this might be right for
Lung Cancer (Non-Small Cell)
Guangdong Association of Clinical Trials 48
Testing effectiveness (Phase 2)Ended earlyNCT04165031
What this trial is testing

LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

Who this might be right for
Advanced Solid TumorNon-Small Cell Lung CancerColorectal Cancer
Eli Lilly and Company 5
Testing effectiveness (Phase 2)Study completedNCT05375994
What this trial is testing

Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

Who this might be right for
Non Small Cell Lung CancerKRAS Activating MutationAdvanced Cancer+3 more
Verastem, Inc. 12
Testing effectiveness (Phase 2)WithdrawnNCT05815186
What this trial is testing

Ladarixin With Sotorasib in Advanced NSCLC - Phase II

Who this might be right for
Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
NYU Langone Health
Testing effectiveness (Phase 2)Looking for participantsNCT07012031
What this trial is testing

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

Who this might be right for
Locally Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8+1 more
National Cancer Institute (NCI) 37
Early research (Phase 1)Ended earlyNCT04892017
What this trial is testing

Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung CancerAdvanced Solid TumorMetastatic Solid Tumor
Deciphera Pharmaceuticals, LLC 91
Large-scale testing (Phase 3)Looking for participantsNCT06345729
What this trial is testing

Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 600
Testing effectiveness (Phase 2)Active Not RecruitingNCT04699188
What this trial is testing

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Who this might be right for
KRAS G12C Mutant Solid TumorsCarcinoma, Non-Small-Cell LungCarcinoma, Colorectal+7 more
Novartis Pharmaceuticals 344
Large-scale testing (Phase 3)Not Yet RecruitingNCT07242274
What this trial is testing

Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)
Jemincare 472
Large-scale testing (Phase 3)Not Yet RecruitingNCT07822542
What this trial is testing

A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Jiangsu Hansoh Pharmaceutical Co., Ltd. 448
Testing effectiveness (Phase 2)Study completedNCT05756153
What this trial is testing

GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

Who this might be right for
Advance Non-small Cell Lung Cancer
Genfleet Therapeutics (Shanghai) Inc. 47
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07543172
What this trial is testing

CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer

Who this might be right for
Advanced Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8
Roswell Park Cancer Institute 29
Next Page